Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?

May 20 @ 6:30 pm 7:30 pm PDT

Manchester Grand Hyatt San Diego, Seaport Ballroom FGH
Supported By: Sanofi & Regeneron

Please join us at ATS 2024 in San Diego for an educational symposium on the shared and unique pathophysiological features of type 2 inflammation–driven asthma and COPD and the real-world impact on patients.

Global experts Mario Castro, Nicola Hanania, and Stephanie Christenson will discuss pathomechanisms of epithelial barrier dysfunction, airway remodeling, and lung function decline, and will share their own perspectives and experiences from clinical practice managing lower airway diseases with underlying type 2 inflammation.

Don’t miss your opportunity to interact with the faculty during the live audience Q&A following the presentations.

Chair: Mario Castro, MD, MPH
L. E. Phillips and Lenora Carr Phillips Professor
Chief, Pulmonary, Critical Care and Sleep Medicine
Vice Chair for Clinical and Translational Research
Director, Frontiers Clinical and Translational Science Institute at the University of Kansas
University of Kansas School of Medicine
Kansas City, Kansas

Nicola Hanania, MD, MS
Director, Airways Clinical Research Center 
Professor of Medicine 
Clinical Science Representative, Faculty Senate
Baylor College of Medicine 
Houston, Texas

Stephanie Christenson, MD, MAS
Associate Professor
Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine
San Francisco, California